Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Gets New Price-Violation Notice From India Regulator

This article was originally published in PharmAsia News

Executive Summary

India's drug-pricing regulator served notice on Cipla for violating the rules in pricing its generic version of the antibiotic ciprofloxacin within the past nine months. At the same time, the Indian Supreme Court is considering another accusation that Cipla overcharged for a range of antibiotics and anti-asthma drugs four years ago. Cipla contends the new notice issued by the National Pharmaceutical Pricing Authority is covered by the pending court case brought by Cipla. Cipla contended in that case that NPPA's penalties were untenable and could not be sustained. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts